110 citations,
October 2019 in “Translational Andrology and Urology” More men are getting benign prostatic hyperplasia, and there are many treatments, from medication to surgery, with new methods being developed.
98 citations,
August 2004 in “BJU international” Medications have become the main treatment for enlarged prostate symptoms, replacing surgery and watchful waiting.
10 citations,
February 2009 in “European urology. Supplement” Treatment for benign prostatic hyperplasia involves drugs that either quickly relieve symptoms or reduce prostate size, with a combination offering more benefits but more side effects.
1054 citations,
February 1998 in “The New England Journal of Medicine” Finasteride reduces urinary issues and surgery need in men with enlarged prostates by over 50%.
52 citations,
February 2006 in “Current pharmaceutical design” 5α-reductase inhibitors and alpha-1 adrenergic antagonists together effectively treat benign prostatic hyperplasia, with long-term benefits.
728 citations,
August 1996 in “The New England Journal of Medicine” Terazosin and finasteride effectively treat BPH, but combining them adds no extra benefit.
14 citations,
May 2016 in “Therapeutic advances in urology” Taking tadalafil and finasteride together is safe and effective for treating urinary symptoms and erectile dysfunction in men with enlarged prostates.
18 citations,
November 2012 in “Current opinion in urology” Finasteride and dutasteride are equally effective and safe for treating benign prostatic hyperplasia.
June 2008 in “Drugs & therapy perspectives” Dutasteride effectively treats benign prostatic hyperplasia, improving symptoms and quality of life.
8 citations,
August 2021 in “Fertility and Sterility” Treatments for enlarged prostate can cause problems with ejaculation, and less invasive options might preserve sexual function better.
11 citations,
January 1991 in “Urology” New hormonal treatments for enlarged prostate show promise for safer, effective non-surgical options.
6 citations,
January 2016 in “International Journal of Trichology” The conclusion is that more hair loss (androgenetic alopecia) is linked to larger prostate size, suggesting hair loss could be an early sign of benign prostatic hyperplasia.
21 citations,
February 2021 in “Frontiers in Endocrinology” Hormones affect prostate health and disease, with certain hormone imbalances linked to prostate cancer and benign prostatic hyperplasia.
90 citations,
March 2017 in “JAMA Internal Medicine” Men over 66 taking medication for prostate enlargement have a higher risk of depression and self-harm, especially in the first 18 months of treatment.
March 2023 in “Translational Andrology and Urology” 5-alpha reductase inhibitors, like finasteride and dutasteride, are used for prostate issues, hair loss, and excessive hair growth, may help with COVID-19, but can cause sexual and mental health side effects, and their use in preventing prostate cancer needs more examination.
3 citations,
January 2019 in “Therapeutic advances in urology” WS PRO 160 I 120 mg effectively treats urinary symptoms from BPH with good safety and tolerability.
237 citations,
December 2001 in “Urology” Blocking the enzyme 5α-reductase can shrink the prostate and help treat enlarged prostate issues.
60 citations,
December 1998 in “Clinical Pharmacology & Therapeutics” Both drugs lower DHT levels, with GI198745 being more effective.
23 citations,
June 1999 in “Clinical Therapeutics” Finasteride is a cost-effective option for treating BPH, reducing risk of urinary issues and surgery.
23 citations,
July 1993 in “Pharmacotherapy” Finasteride treats enlarged prostate and baldness, but may cause limited urinary improvement and sex-related side effects.
4 citations,
December 2013 in “Archivio italiano di urologia, andrologia” Dutasteride reduces hospitalization and prostate cancer risk compared to finasteride, potentially offsetting its higher cost.
May 2024 in “KIU journal of health science” Kolaviron and quercetin may help treat prostate issues.
April 2017 in “The Journal of Urology” Finasteride before TURP reduces blood loss and improves early postoperative quality of life.
223 citations,
December 2010 in “The Journal of Sexual Medicine” Some patients taking finasteride or dutasteride may have ongoing sexual problems and depression even after stopping the medication.
75 citations,
January 2014 in “Korean Journal of Urology” 5α-reductase inhibitors can cause sexual problems, higher risk of aggressive prostate cancer, and depression.
70 citations,
July 2005 in “Journal of Ethnopharmacology” Ganoderma lucidum, a type of mushroom, may help treat enlarged prostate by blocking testosterone conversion.
64 citations,
March 2006 in “Food Chemistry” The triterpenoids from Ganoderma lucidum can block testosterone effects and may help treat enlarged prostate.
57 citations,
July 2016 in “The Journal of Sexual Medicine” 5α-reductase inhibitors increase the risk of sexual dysfunction, especially in men with enlarged prostate.
28 citations,
August 2014 in “Cancer Causes & Control” Taking 5α-reductase inhibitors does not significantly increase the risk of breast cancer in men.
15 citations,
November 2015 in “Pharmacopsychiatry” α-Blockers and 5-ARIs for BPH can cause sexual dysfunction, including erectile and ejaculatory issues.